Poster Spotlight 3: Emerging Paradigms of CDK Inhibitor and Antibody Drug Conjugate Resistance in Metastatic Breast Cancer
Session Details
The text of the abstracts will be posted on Monday, November 24.
Moderator
Seth A Wander, Mass General Cancer Center, Boston, MA
Presentation numberPD3-01
Single cell analysis identifies genes that enable survival of drug tolerant persisters upon treatment with CDK4/6 inhibitors
Yuki Matsunaga, UT Southwestern Medical Center, Dallas, TX
Presentation numberPD3-02
Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-World (RW) Clinical-Multiomics Data
Kristin M. Zimmerman Savill, Flatiron Health, New York, NY
Presentation numberPD3-03
Preclinical Modeling of CDK4/6 Inhibitor and Endocrine Therapy Resistance in ER+ Metastatic Breast Cancer Using Patient-Derived Xenografts
Cristina Molina, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Presentation numberPD3-04
Chromatin remodelling is involved in resistance to CDK4/6 inhibitors in ER+ breast cancer
Felice Pepe, University of Naples Federico II, Naples, Italy
Presentation numberPD3-05
Targeting FGFR4 with an antibody-drug conjugate in hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer progressing to CDK4/6 inhibitors and endocrine therapy
Fara Braso-Maristany, Fundació de Recerca Clínic Barcelona, Barcelona, Spain
Presentation numberPD3-06
Discussant: CDKi Resistance
Karthik V Giridhar, Mayo Clinic, Rochester, MN
Presentation numberPD3-07
Deciphering resistance mechanisms to fam-trastuzumab deruxtecan-nxki in metastatic breast cancer using real-world data
Alka A Potdar, Eisai Inc., Woodcliff Lake, NJ
Presentation numberPD3-08
Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort.
Francois Poumeaud, Oncopole Claudius Regaud, Toulouse, France
Presentation numberPD3-09
Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network
Ana C Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA
Presentation numberPD3-10
Biomarkers of primary resistance to sacituzumab govitecan in metastatic triple negative breast cancer
Elie Rassy, Gustave Roussy, Villejuif, France
Presentation numberPD3-11
Overcoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy
Jangsoon Lee, University of Hawai‘i Cancer Center, Honolulu, HI
Presentation numberPD3-12
Discussant: ADC Resistance
Rachel O Abelman, Mass General Cancer Center/Harvard Medical School, Boston, MA